Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Rhea-AI Summary

Nanobiotix has reported its voting rights and share count as of November 30, 2021. The company has 34,825,872 shares outstanding, with a total of 36,003,389 voting rights (gross) and 35,985,166 voting rights (net). This information aligns with regulatory requirements set by the French Financial Markets Authority.

Nanobiotix, listed on both Euronext Paris and Nasdaq, specializes in innovative therapeutic approaches in biotechnology, focusing on oncology and has market authorization for its lead candidate, NBTXR3.

Positive

• Nanobiotix has 34,825,872 shares outstanding as of November 30, 2021.
• Total voting rights reported as 36,003,389 (gross) and 35,985,166 (net), signaling strong governance.

Negative

• None.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority)

PARIS--(BUSINESS WIRE)-- Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, gross (1)	Total voting rights, net (2)
November 30, 2021	34,825,872	36,003,389	35,985,166

⁽¹⁾ The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

⁽²⁾ The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

***

About NANOBIOTIX: http://www.nanobiotix.com
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity.

The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

The company's resources are primarily devoted to the development of its lead product candidate–NBTXR3—which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

For more information about Nanobiotix, visit us at http://www.nanobiotix.com or follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005209/en/

Nanobiotix

Nanobiotix Communications

Brandon Owens

VP, Communications

+1 (617) 852-4835

contact@nanobiotix.com

Nanobiotix Investor Relations

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388

investors@nanobiotix.com

Media Relations

France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

plgermain@ulysse-communication.com

US – Porter Novelli

Dan Childs

+1 (781) 888-5106

dan.childs@porternovelli.com

Source: Nanobiotix

FAQ

What is the total number of shares outstanding for NBTX as of November 30, 2021?

Nanobiotix has 34,825,872 shares outstanding as of November 30, 2021.

How many voting rights does NBTX have as of November 30, 2021?

Nanobiotix has a total of 36,003,389 voting rights (gross) and 35,985,166 voting rights (net) as of November 30, 2021.

What does the latest press release from Nanobiotix indicate about its shares?

The press release indicates the number of shares outstanding and total voting rights as of November 30, 2021.

What stock exchanges is NBTX listed on?

Nanobiotix is listed on Euronext Paris and Nasdaq.

When did Nanobiotix gain market authorization for NBTXR3?

Nanobiotix has already achieved market authorization for NBTXR3 in Europe for the treatment of soft tissue sarcoma.